Emergent BioSolutions Receives New Contract Modification for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance of Public Health Preparedness
GAITHERSBURG, Md. , Sept. 09, 2025 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today announced that a contract modification has been executed in the amount of $56...
Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use
GAITHERSBURG, Md. , Sept. 02, 2025 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received a $30 million contract modification from the Biomedical...
Emergent BioSolutions Underscores Continued Support of Increasing Naloxone Awareness Through Public Education Campaign on International Overdose Awareness Day
Pro Football Hall of Famer and Ready to Rescue campaign spokesperson, Emmitt Smith , and Release Recovery Founder/CEO, Zac Clark , plan to visit several U.S. college campuses to educate on opioid...
Emergent BioSolutions Supports Voices for Awareness and Facing Fentanyl Now on August 21, 2025 for National Fentanyl Prevention and Awareness Day™
GAITHERSBURG, Md. , Aug. 21, 2025 (GLOBE NEWSWIRE) — As opioid emergencies continue to be the leading cause of accidental death in the United States , 1 Emergent BioSolutions (NYSE: EBS)...
Emergent BioSolutions Reports Second Quarter 2025 Financial Results
Second Quarter 2025 Total Revenues of $140.9 million , above Q2 guidance by $21 million Second Quarter 2025 Net Loss of $12.0 million and Net Loss Margin of (9)%, an improvement of 96% and 10,200...
New Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential Antiviral Treatment for Mpox
Ongoing mpox outbreak continues to be a global health threat and is driving need for greater therapeutic research and innovation GAITHERSBURG, Md. , July 28, 2025 (GLOBE NEWSWIRE) — Emergent...
Emergent Applauds Availability of Over-the-Counter Naloxone in U.S. House of Representatives
GAITHERSBURG, Md. , July 28, 2025 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today announces its recognition of the U.S. House of Representatives for adding over-the-counter...
Emergent BioSolutions to Report Second Quarter 2025 Financial Results on August 6, 2025
GAITHERSBURG, Md. , July 15, 2025 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, August 6, 2025 , at 5:00 pm eastern time to discuss the...
Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense Preparedness Efforts
GAITHERSBURG, Md. , July 08, 2025 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract modification has been secured to deliver CNJ-016 ® [Vaccinia Immune...
Emergent BioSolutions Expands NARCANDirect® to Offer KLOXXADO® (naloxone HCl) Nasal Spray 8 mg and Convenience Kits Amid Changes in Overdose Death Rate
Starting July 1, 2025, additional opioid overdose response tools will be available to continue addressing evolving patient and customer needs to combat public health crisis GAITHERSBURG, Md. , July...
Emergent BioSolutions Secures $62.4 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Bolster U.S. Biodefense Supply
GAITHERSBURG, Md. , June 23, 2025 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today announced it has been awarded a $62.4 million contract modification from the...
Emergent BioSolutions Announces Addition to Russell 3000® Index
GAITHERSBURG, Md. , June 20, 2025 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today announced the Company will be added to the broad-market Russell 3000 ® Index , effective...